Dr. Ehdaie weighs in on focal therapy with MRgFUS for GG2/3 prostate cancer
In this video, Behfar Ehdaie, MD, MPH, compared magnetic resonance (MR)–guided focused ultrasound (MRgFUS) with other forms of focal therapy used to treat prostate cancer as well as the learning curve associated with this specific therapy.
During the 2021 AUA Annual Meeting, Ehdaie presented a study showing that in some men with intermediate-risk prostate cancer, MRgFUS focal therapy may be an effective alternative to radical therapy that improves quality-of-life measures such as sexual function and urinary incontinence.
Ehdaie is an assistant member of the urology service department of surgery at Memorial Sloan Kettering Cancer Center, New York City, New York.
Lenvatinib/pembrolizumab compares favorably with frontline standards in renal cell carcinoma
February 2nd 2024“Combination therapy with lenvatinib plus pembrolizumab provides a comparable OS, and a trend of improvement in PFS and response outcomes, compared with most current global SOC therapies for treatment-naïve patients with advanced renal cell carcinoma,” the study authors wrote.
First-line pembrolizumab/lenvatinib shows efficacy for advanced non–clear cell RCC
January 29th 2024“Updated efficacy and safety results continue to support pembrolizumab plus lenvatinib as a first-line treatment option for patients with advanced non–clear cell RCC,” lead study author Martin H. Voss, MD.
